Viyash Scientific Limited delivered its strongest quarterly performance in company history during Q4 FY26. The firm reported an EBITDA surpassing INR 200 crore, representing a 59.6% year-on-year growth for the full fiscal year. This transformation was fueled by the successful integration of business operations, improved operating leverage, and strategic focus on complex formulations and API segments, positioning the company for sustained long-term growth and value creation in FY27 and beyond.
Fiscal Performance Highlights
For the full financial year 2026, Viyash Scientific achieved total revenue of INR 3,420 crore, marking a 13.8% increase over the previous year. The fourth quarter was particularly robust, with total revenue reaching INR 920 crore, a 19.1% growth year-on-year. Profit after tax recorded a significant turnaround, swinging from a loss in the previous period to a profit of INR 66 crore for the quarter.
Strategic Business Transformation
The company’s shift toward complex, high-potent products and internal API integration has drastically improved margins. Gross margins for the full year expanded by 321 basis points to 54.3%. Management highlighted the successful integration of corporate functions and operations as a key driver of current synergies, which are currently tracking at an annualized rate of INR 60 crore, with expectations to reach INR 125 crore to 150 crore over the next 12 to 18 months.
Growth Drivers in Animal Health and CDMO
The Animal Health segment, which remained stagnant for several years, achieved a INR 400 crore run rate in FY26. The firm is aggressively expanding its product portfolio, with a focus on companion animals and innovator-partnered life cycle management. Additionally, the CDMO business continues to gain traction, with strong partnerships established among 8 to 10 major global innovators. R&D investments are being significantly scaled to support this momentum, particularly in complex onco-lab development and formulation manufacturing.
Future Outlook
Looking ahead to FY27, Viyash Scientific is prioritizing the strengthening of merger synergies, operational efficiency, and selective inorganic growth opportunities. With a deleveraged balance sheet and a focus on long-term product pipelines, the leadership team anticipates sustained double-digit growth. The company remains committed to maintaining its healthy gross margin profile while continuing to scale its footprint in key markets across Europe, India, and Brazil.
Source: BSE
